memantine has been researched along with Atrophy in 8 studies
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer's disease (AD) over the course of 52 weeks of treatment with memantine or placebo." | 9.16 | Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. ( Barkhof, F; Fox, NC; Lemming, O; Phul, R; Scheltens, P; Wilkinson, D, 2012) |
| "To study the effect of memantine on apathy, a common symptom of behavioral variant frontotemporal dementia (bvFTD)." | 7.79 | A case of apathy due to frontotemporal dementia responsive to memantine. ( Black, SE; Chow, TW; Graff-Guerrero, A; Houle, S; Links, KA; Pollock, BG; Wilson, AA, 2013) |
| "The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value." | 7.73 | Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer's disease (AD) over the course of 52 weeks of treatment with memantine or placebo." | 5.16 | Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. ( Barkhof, F; Fox, NC; Lemming, O; Phul, R; Scheltens, P; Wilkinson, D, 2012) |
| "To study the effect of memantine on apathy, a common symptom of behavioral variant frontotemporal dementia (bvFTD)." | 3.79 | A case of apathy due to frontotemporal dementia responsive to memantine. ( Black, SE; Chow, TW; Graff-Guerrero, A; Houle, S; Links, KA; Pollock, BG; Wilson, AA, 2013) |
| "The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value." | 3.73 | Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "The diagnostic criteria of catatonia and frontotemporal dementia partly overlap." | 1.39 | Three patients with mood disorders showing catatonia and frontotemporal lobes atrophy. ( Arai, H; Iseki, E; Utumi, Y, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Utumi, Y | 1 |
| Iseki, E | 1 |
| Arai, H | 1 |
| Borre, YE | 1 |
| Panagaki, T | 1 |
| Koelink, PJ | 1 |
| Morgan, ME | 1 |
| Hendriksen, H | 1 |
| Garssen, J | 1 |
| Kraneveld, AD | 1 |
| Olivier, B | 1 |
| Oosting, RS | 1 |
| Ene-Stroescu, V | 1 |
| Nguyen, T | 1 |
| Waiblinger, BE | 1 |
| Annweiler, C | 1 |
| Wilkinson, D | 1 |
| Fox, NC | 1 |
| Barkhof, F | 1 |
| Phul, R | 1 |
| Lemming, O | 1 |
| Scheltens, P | 1 |
| Links, KA | 1 |
| Black, SE | 1 |
| Graff-Guerrero, A | 1 |
| Wilson, AA | 1 |
| Houle, S | 1 |
| Pollock, BG | 1 |
| Chow, TW | 1 |
| Yücel, YH | 1 |
| Gupta, N | 1 |
| Zhang, Q | 1 |
| Mizisin, AP | 1 |
| Kalichman, MW | 1 |
| Weinreb, RN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease[NCT00862940] | Phase 4 | 277 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Estimated mean changes in total HCV (NCT00862940)
Timeframe: Baseline to 1 year
| Intervention | mm^3/year (Mean) |
|---|---|
| Memantine 10 mg Tablets Twice Daily | -218 |
| Placebo Tablets Twice Daily | -220 |
Adjusted mean change from baseline on cognitive and behavioural scores. COWAT: Verbal fluency test. The patient was asked to, during 1 minute, generate as many words as possible beginning with three pre-specified letters. The total score was calculated as the sum of acceptable words generated, with higher scores indicating lower cognitive impairment (NCT00862940)
Timeframe: Baseline to 1 year
| Intervention | Scale scores (Least Squares Mean) |
|---|---|
| Memantine 10 mg Tablets Twice Daily | 0.78 |
| Placebo Tablets Twice Daily | -0.90 |
Adjusted mean change from baseline on cognitive and behavioural scores. MMSE: Brief, structured examination of mental status that assesses orientation, memory, attention, naming, comprehension, and praxis. The range is 0 to 30, with a lower score indicating a worse mental state (NCT00862940)
Timeframe: Baseline to 1 year
| Intervention | Scale scores (Least Squares Mean) |
|---|---|
| Memantine 10 mg Tablets Twice Daily | -0.50 |
| Placebo Tablets Twice Daily | -0.74 |
Measures direct changes in total brain volume per visit interval (screening to Week 4, 42, or 52 or from Week 4 to Week 42 or 52) (NCT00862940)
Timeframe: Baseline to 1 year
| Intervention | mL/year (Mean) |
|---|---|
| Memantine 10 mg Tablets Twice Daily | 15.24 |
| Placebo Tablets Twice Daily | 15.32 |
1 review available for memantine and Atrophy
| Article | Year |
|---|---|
[Vitamin D and Alzheimer's disease: from an intriguing idea to a therapeutic option].
Topics: Acetylcholine; Alzheimer Disease; Amyloid; Animals; Anti-Inflammatory Agents; Antioxidants; Atrophy; | 2014 |
1 trial available for memantine and Atrophy
| Article | Year |
|---|---|
Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Atrophy; Brain; Cholinesterase Inh | 2012 |
6 other studies available for memantine and Atrophy
| Article | Year |
|---|---|
Three patients with mood disorders showing catatonia and frontotemporal lobes atrophy.
Topics: Aged; Atrophy; Catatonia; Combined Modality Therapy; Dopamine Agents; Electroconvulsive Therapy; Fem | 2013 |
Neuroprotective and cognitive enhancing effects of a multi-targeted food intervention in an animal model of neurodegeneration and depression.
Topics: Animals; Atrophy; Cell Death; Cognition Disorders; Depressive Disorder; Disease Models, Animal; Hipp | 2014 |
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy.
Topics: Adolescent; Amantadine; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Atrophy; Catato | 2014 |
New developments in the treatment of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Atrophy; Biomarkers; Brain; Choli | 2009 |
A case of apathy due to frontotemporal dementia responsive to memantine.
Topics: Aged; Apathy; Atrophy; Dopamine Agents; Follow-Up Studies; Frontal Lobe; Frontotemporal Dementia; Hu | 2013 |
Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma.
Topics: Animals; Atrophy; Cell Count; Cytoprotection; Disease Models, Animal; Excitatory Amino Acid Antagoni | 2006 |